WPRIM Management System> DCMS> Journal of Lung Cancer> 2003> 2> 1

Volume: 2 Issue: 1

1. Inhibiting NF-kappaB Activation by Triptolide Enhances TRAIL-induced Cell Death in Lung Cancer Cells. Page:61—68
2. Relationship between Tumor Angiogenesis and Micrometastases in The Regional Lymph Nodes of Patient with Stage I Non-Small Cell Lung Cancer. Page:54—60
3. Polymorphisms in ERCC1 and ERCC2/XPD and Survival in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin Based Chemotherapy. Page:44—53
4. Efficacy of Topotecan as a Second-Line Treatment of Small-Cell Lung Cancer in Patients with Refractory and Sensitive Disease: Retrospective Study. Page:37—43
5. Lack of the Difference in Outcome between N2 and N3 Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy; A Retrospective Analysis of 186 Patients. Page:31—36
6. Phase II Study of 3-D Conformal Radiotherapy and Concurrent MVP (Mitomycin-C+Vinblastine+Cisplatin) Chemotherapy for Unresectable Non-Small Cell Lung Cancer. Page:23—30
7. Clinical Response of Docetaxel Plus Cisplatin and Paclitaxel Plus Carboplatin Chemotherpy in Non-Small Cell Lung Cancer. Page:16—22
8. Molecular Aspects of Radiotherapy. Page:10—15
9. Adjuvant Chemotherapy for Completely Resected Non-Small Cell Lung Cancer. Page:6—9
10. Screening for Lung Cancer with Low-Dose Computed Tomography. Page:1—5

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.